Efficacy and safety of rufinamide as adjunctive therapy in patients with Lennox Gastaut syndrome: A systematic review and Meta-analysis.

Lennox–Gastaut syndrome is one of the childhood-onset epilepsy syndromes characterized by a triad of drug-resistant epilepsy with multiple seizure types, with a high seizure burden (predominantly tonic seizure, atonic seizure, atypical absence seizure, and myoclonic seizure), significant psychomotor retardation, and slow spike-wave pattern in electroencephalogram (EEG) [1]. Around 20% cases of LGS have a history of epileptic spasms and LGS constitutes 1-4% of all children with epilepsy [2]. No antiseizure medications (ASMs) have been proven to achieve complete seizure freedom uniformly in all cases of LGS.

0